41 results about "Geographic atrophy" patented technology

A method implemented by one or more computer devices includes receiving fundus autofluorescence (FAF) image data for a retina of a subject. The FAF image data includes a first FAF image associated with a first point in time. An image input for a deep learning system is generated using the FAF image data. A predicted growth output for a geographic atrophy (GA) lesion in the retina is generated using the image input via the deep learning system. The predicted growth output is associated with at least one future time point after the first time point.

Embodiments disclosed herein generally relate to predicting geographic-atrophy lesion growth and / or geographic atrophy lesion size in an eye. The predictions can be generated by processing a data object using a neural network. The data object may include a three-dimensional data object representing a depiction of at least part of the eye or a multi-channel data object representing one or more decorresponding pictions of at least part of the eye. The neural network can include a convolutional multi-task neural network that is trained to learn features that are predictive of both lesion-growth and lesion-size outputs.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

An electronic device is disclosed. The device receives retinal images and patient data corresponding to the retinal images. The device can train a first machine learning model (“model”) based on a first group of the retinal images and patient data corresponding to the first group and a second model based on a second group of the retinal images and patient data corresponding to the second group. The electronic device can generate a first prediction based on the first subset of a third group of the retinal images and a second prediction based on the second subset of the third group. After training the first model and the second model, the device can train a third model to predict a geographic atrophy progression in an eye of a patient based on the first and second predictions, the first and second subsets, and patient data corresponding to the first and second subset.

A computer-based method and system for predicting future geographic atrophy (GA) lesion growth. An optical coherence tomography (OCT) volume for a retina of a subject associated with a first point in time is received by a process over a network. A segmentation model is used to generate a segmented volume corresponding to the OCT volume, the segmented volume comprising a plurality of 3D segments. For each 3D segment of the plurality of 3D segments, a map output is generated. A set of biomarker values is computed for a corresponding set of biomarker features using the map output. A prediction system is used to generate a prediction output that predicts a progression of a GA lesion in the retina with respect to a future point in time after the first point in time using at least one of the set of biomarker values or the map output.

An apparatus for delivering therapeutic agent to an eye comprises a body, a cannula, a hollow needle, and an actuation assembly. The cannula extends distally from the body and is sized and configured to be insertable between a choroid and a sclera of a patient's eye. The actuation assembly is operable to actuate the needle relative to the cannula to thereby drive a distal portion of the needle along an exit axis that is obliquely oriented relative to the longitudinal axis of the cannula. The cannula may be inserted through a sclerotomy incision to position a distal end of the cannula at a posterior region of the eye, between the choroid and sclera. The needle may be advanced through the choroid to deliver the therapeutic agent adjacent to the potential space between the neurosensory retina and the retinal pigment epithelium layer, adjacent to the area of geographic atrophy.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

Provided herein are systems utilizing machine learning in detecting geographic atrophy. The system can include at least one processor, a memory, and a computing platform including the at least one processor and the memory. The computing platform can be configured to receive volumetric scan images, determine a position of each of the volumetric scan images, generate, using a trained detection algorithm, a probabilistic likelihood that each scan is informative of geographic atrophy or neovascular age-related macular degeneration, include high probability scans in a dataset, determine, using the included scans in the dataset, whether geographic atrophy or neovascular age-related macular degeneration is present or likely to occur, and output, by the detection algorithm, information indicating whether or not geographic atrophy or neovascular age-related macular degeneration is present or likely to occur.

This disclosure provides a method and system for evaluating geographic atrophy (GA) using a custom machine learning model. A set of fundus autofluorescence (FAF) images of a subject is received. Input to the machine learning model is generated using multiple FAF images. The input includes a subset of features selected from a plurality of image features. The plurality of image features includes at least one of a plurality of shape features and a plurality of texture features. The selection of the subset of features from the plurality of features is based on evaluating the performance of a set of trained models used to process at least two different combinations of the plurality of features. A set of geographic atrophy (GA) progression parameters is predicted based on the input via the custom machine learning model.

Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.

Avacincaptad pegol, also known under the trademarks Izervay or Zimura, is a molecule comprising an aptamer sequence and a polyethylene glycol polymer (PEG) -moiety. The aptamer sequence binds to complement C5-protein, which C5 protein is known to be involved in many eye diseases. Avacincaptad pegol is approved to treat Age-related Macular Degeneration (AMD) secondary to Geographic Atrophy (GA) and is applied by intravitreal injection into the eye. The pharmaceutical product is currently only offered as a liquid in a vial. This patent application discloses Avacincaptad in a more stable presentation, namely in a pre-filled syringe, which surprisingly results in very significantly improved stability of the product.

To provide compositions and methods for treating retinal diseases or disorders using RPE cells.SOLUTION: The present invention provides a pharmaceutical composition for treating or slowing the progression of a retinal disease or disorder in a subject, comprising a therapeutically effective amount of retinal pigment epithelium (RPE) cells. The therapeutically effective amount of RPE cells is about 50,000 and 5,000,000 cells. The composition is formulated for implantation to a region covering the geographic atrophy (GA) lesion or a region covering the fovea in a subject.SELECTED DRAWING: None

A method and system for evaluating geographic atrophy in a retina. A set of fundus autofluorescence (FAF) images of the retina is received. An input is generated for a machine learning system using the set of fundus autofluorescence images. A lesion area is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the set of fundus autofluorescence images. A lesion growth rate is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the input.

A method, system, and computer program product for evaluating a geographic atrophy lesion. An image of a geographic atrophy (GA) lesion is received. A first set of values is determined for a set of shape features using the image. A second set of values is determined for a set of textural features using the image. GA progression for the GA lesion is predicted using the first set of values and the second set of values.

This disclosure provides peptide based compounds, compositions, and methods to treat medical disordeds, such as complement-mediated disorders, including complement C1s-mediated disorders, such as acute antibody-mediated rejection, amyotrophic lateral sclerosis, autoimmune blistering disease, bullous pemphigoid, geographic atrophy, or Guillain-Barre Syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of the compound.

The present disclosure relates to the treatment and / or prevention of age-related macular degeneration (AMD), including the advanced form of dry AMD referred to as Geographic Atrophy (GA). In particular, the present disclosure provides novel therapeutic antibodies that target components of the alternative pathway of the complement activation system, including complement factor H-related (CFHR) 4.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The present disclosure relates to the treatment and / or prevention of age-related macular degeneration (AMD), including both neovascular AMD (“wet” AMD) and non-neovascular AMD (“dry” AMD), as well as advanced forms of non-neovascular AMD (geographic atrophy or GA). In particular, the present disclosure provides novel therapeutic bispecific antibodies that target components of the alternative pathway of the complement activation system.

A method, implemented by one or more computer devices, includes receiving fundus autofluorescence (FAF) image data for a retina of a subject. The FAF image data includes a first FAF image associated with a first point in time. An image input for a deep learning system is generated using the FAF image data. A predicted growth output for a geographic atrophy (GA) lesion in the retina is generated via the deep learning system using the image input. The predicted growth output is associated with at least one future point in time after the first point in time.

Aspects of the present disclosure relate to compositions and methods for modulating the translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The present disclosure is based, in part, on isolated nucleic acids that bind to an mRNA transcript of a gene involved in L-serine biosynthesis, such as serine palmitoyltransferase long chain base subunit 1 (SPTLC1). In some embodiments, the compositions of the present disclosure are useful for the treatment of diseases or conditions associated with dysregulation of L-serine biosynthesis, such as retinal diseases (e.g., MacTel2 and age-related macular degeneration (AMD), such as AMD with geographic atrophy), HSAN1 (e.g., HSAN1 (a)), diabetic retinopathy, peripheral neuropathy (e.g., neuropathy), and the treatment of diseases or conditions associated with dysregulation of L-serine biosynthesis, such as retinal diseases (e.g., MacTel2 and age-related macular degeneration (AMD), such as AMD with geographic atrophy). ), neurodegenerative disorders (e.g., Parkinson's disease, Friedel's ataxia, motor neuron disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), etc.), spasmodic paraplegia or psychiatric disorders (e.g., neurodegenerative disorders, neurodegenerative disorders, etc. ), resistant depression, refractory depression, schizophrenia, and / or refractory schizophrenia.

A method and system for assessing geographic atrophy in the retina is provided, comprising: receiving a set of fundus autofluorescence (FAF) images of the retina at a machine learning system; receiving a set of optical coherence tomography (OCT) images of the retina at a machine learning system; and predicting lesion growth rates for geographic atrophy lesions in the retina using the set of FAF images and the set of OCT images via the machine learning system.

A method for automatic prediction of a geographic atrophy (GA) from optical coherence tomography (OCT) data of a retina of a patient includes segmenting the OCT data using a first segmentation algorithm for providing a GA segmentation of the geographic atrophy in the retina, and segmenting the OCT data for providing structure-specific segmentations of certain structures in the retina. The method further includes determining a GA contour in the retina using the GA segmentation, and for each margin point of the GA contour, providing a number of quantifiable features using the GA contour and structure-specific segmentations such that a feature vector including the quantifiable features is provided for each margin point. The method further includes providing a respective local progression rate for each of the margin points by applying a spatial regression model having as inputs the GA contour and the feature vectors for the margin points.

The invention relates to a construction method and application of an animal model with retina geographic atrophy (GA) accompanied by choroidal neovascularization (CNV) symptoms. According to the method, sodium iodate is injected at multiple points in the subretinal space of cynomolgus monkeys, so that the retina has typical and clinically close retinopathy GA and CNV symptoms, and the blank of animal models for preclinical evaluation of multi-target drugs for treating GA and CNV at present is filled.

A method and system for evaluating geographic atrophy in a retina. A set of fundus autofluorescence (FAF) images of the retina is received. An input is generated for a machine learning system using the set of fundus autofluorescence images. A lesion area is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the set of fundus autofluorescence images. A lesion growth rate is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the input.

Disclosed is a method of treating a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. Also disclosed is a method of delaying the progression of vision loss in a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. The methods comprise administering an effective amount of gildeuretinol acetate to the patient.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.

A processing system automatically detects regions of GA-related biomarkers from medical images. The processing system obtains a volumetric image of an eye comprising a set of image slices. For each of the image slices, the processing system applies a machine learning model to generate likelihood values characterizing inferred regions of GA-related biomarkers. The machine learning model is trained to learn relationships between training image slices from training volumetric images and labels identifying regions of GA-related biomarkers in the training volumetric images. The processing system generates from the likelihood values, an inference map that spatially maps the inferred regions of the GA-related biomarkers. The processing system furthermore outputs a visual representation of the inference map, such as a two dimensional enface map or a three-dimensional map, to a display device.

A method, system, and computer program product for evaluating a geographic atrophy lesion. An image of a geographic atrophy (GA) lesion is received. A first set of values is determined for a set of shape features using the image. A second set of values is determined for a set of textural features using the image. GA progression for the GA lesion is predicted using the first set of values and the second set of values.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.

Recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant is provided. Also provided are a method for delivering the transgene to the retina, and a method for treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration by contacting retinal cells with rAAV. The variant AAV capsid protein may contain a peptide insertion ("heterogeneous peptide" or "peptide insertion") of about 7 to 20 amino acids within the GH loop of the capsid protein, preferably within the surface-exposed region of the GH loop, compared to the corresponding parental AAV capsid protein.